Structure-based design of potent CDK4 selective inhibitor.

被引：0

作者：

Honma, T ^{[1
]}

Hayashi, K ^{[1
]}

Kawanishi, N ^{[1
]}

Yoshizumi, T ^{[1
]}

Hashimoto, N ^{[1
]}

Sugimoto, T ^{[1
]}

Nakamura, K ^{[1
]}

Takaki, T ^{[1
]}

Machida, T ^{[1
]}

Fukasawa, K ^{[1
]}

Hirai, H ^{[1
]}

Iwama, T ^{[1
]}

Ikeura, C ^{[1
]}

Ikuta, M ^{[1
]}

Kamata, K ^{[1
]}

Suzuki-Takahashi, I ^{[1
]}

Hayama, T ^{[1
]}

机构：

[1] Banyu Pharmaceut Co Ltd, Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2001年 / 221卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

136-MEDI

引用

页码：U24 / U24

页数：1

共 50 条

[31] FCN-437: A novel, potent and selective oral inhibitor of CDK4/6 for the treatment of solid tumors
Lin, Shu
Zhao, Xingdong
Li, Tongshuang
Zhang, Huajie
Tan, Haohan
Wang, Xianlong
Jiang, Lihua
Liu, Yanxin
Sun, Jing
Li Linghu
Liu, Qihong
Li, Zhifu
Zhang, Weipeng
Wang, Weibo
CANCER RESEARCH, 2019, 79 (13)
[32] Structure-based design of a selective heparanase inhibitor as an antimetastatic agent
Ishida, K
Hirai, G
Murakami, K
Teruya, T
Simizu, S
Sodeoka, M
Osada, H
MOLECULAR CANCER THERAPEUTICS, 2004, 3 (09) : 1069 - 1077
[33] Structure-based inhibitor design
Craig, SP
Eakin, AE
VITAMINS AND HORMONES - ADVANCES IN RESEARCH AND APPLICATIONS, VOL 58, 2000, 58 : 149 - +
[34] Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor
Makiko Kobayashi
Ikuko Takahashi-Suzuki
Toshiyasu Shimomura
Yoshikazu Iwasawa
Hiroshi Hirai
Investigational New Drugs, 2011, 29 : 921 - 931
[35] Metamorphosis of paroxetine into a highly potent and selective GRK2 inhibitor via structure-based drug design
Waldschmidt, Helen
Homan, Kristoff
Cruz-Rodriguez, Osvaldo
Cato, Marilyn
Bouley, Renee
Wilson, Michael
Cannavo, Alessandro
Song, Jianliang
Cheung, Joseph
Kirchhoff, Paul
Koch, Walter
Tesmer, John
Larsen, Scott
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
[36] Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement
Buijnsters, Peter
De Angelis, Meri
Langlois, Xavier
Rombouts, Frederik J. R.
Sanderson, Wendy
Tresadern, Gary
Ritchie, Alison
Trabanco, Andres A.
VanHoof, Greet
Van Roosbroeck, Yves
Andres, Jose-Ignacio
ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (09): : 1049 - 1053
[37] A phase I and pharmacokinetic (PK) study of continuous daily administration of P1446A-05, a potent and specific oral Cdk4 inhibitor.
Hao, Desiree
Chu, Quincy
Welch, Stephen
Yau, Cindy Y. F.
Spratlin, Jennifer L.
Tang, Patricia
MacKenzie, Mary J.
Townsley, Carol A.
Arndt, Diane
Johnson, Laureen
Trapsa, Daniela
Degendorfer, Pamela
Kulkarni, Sujay
Jawlekar, Gajendra
Dhobe, Poornima
Oza, Amit M.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[38] Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors
Bhide, Rajeev S.
Keon, Alec
Weigelt, Carolyn
Sack, John S.
Schmidt, Robert J.
Lin, Shuqun
Xiao, Hai-Yun
Spergel, Steven H.
Kempson, James
Pitts, William J.
Carman, Julie
Poss, Michael A.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (21) : 4908 - 4913
[39] The effect of CDK4 inhibitor to AML
Wang, Jie
Briesewitz, Roger
ACTA PHARMACOLOGICA SINICA, 2006, 27 : 115 - 115
[40] Structure-based library design and the discovery of a potent and selective mast cell β-tryptase inhibitor as an oral therapeutic agent
Liang, Guyan
Aldous, Suzanne
Merriman, Gregory
Levell, Julian
Pribish, James
Cairns, Jennifer
Chen, Xin
Maignan, Sebastien
Mathieu, Magali
Tsay, Joseph
Sides, Keith
Rebello, Sam
Whitely, Brian
Morize, Isabelle
Pauls, Henry W.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (02) : 1049 - 1054

← 1 2 3 4 5 →